Pulmonary Nodules, Multiple

2

Review clinical trials related to Pulmonary Nodules, Multiple. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath

The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) markers. This model aims to accurately differentiate benign from malignant nodules in individuals harboring pulmonary nodules. The primary objectives it strives to accomplish are: 1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in distinguishing benign and malignant pulmonary nodules. 2. To evaluate the diagnostic effectiveness of an AI model that employs exhaled breath VOC biomakers to identify specific types of malignant nodules, including lung adenocarcinoma, lung squamous cell carcinoma, and small cell lung cancer. 3. To explore and identify key characteristic VOCs combinations that are associated with EGFR site mutations in malignant nodules, further modeling and evaluating the classification performance. By utilizing this comprehensive approach, the study hopes to contribute significantly to early detection and accurate classification of pulmonary nodules, ultimately leading to improved patient care and treatment outcomes.

Participants needed: 3,000
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: ChromX HealthUpdated: Dec 24, 2025Locations: 15
Eligibility criteria

18-80 years old; [+4]

The maximum diameter of pulmonary nodules is greater than 30 mm; [+11]

Status: Recruiting

An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules

A single-center, open-label dose-escalation design to evaluate the safety and efficacy of KN5001 in patients with pulmonary nodules.

Participants needed: 24
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital with Nanjing Medical UniversityUpdated: Dec 1, 2025Locations: 1
Eligibility criteria

Subjects voluntarily sign the informed consent form, understand this clinical st... [+2]

Subjects who are known to have allergic reactions, hypersensitivity reactions, i... [+10]